ENTG Stock Analysis: Entegris | NASDAQ
Semiconductor Equipment & Materials | NASDAQ, USA | Market Cap: 22.524m USD | 12M Return: 87.8% | US29362U1043 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 515M
EPS Trend: 76.9%
Qual. Beats: 4
Rev. Trend: -9.5%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Entegris, Inc. (NASDAQ: ENTG) is a U.S.-based provider of advanced materials and process solutions serving the semiconductor industry and other high-technology manufacturing sectors. Founded in 1966 and headquartered in Billerica, Massachusetts, the company operates globally across North America, Taiwan, South Korea, Japan, China, Europe, and Southeast Asia. It is classified within the GICS Semiconductor Materials & Equipment sub-industry, a critical upstream segment of the chip supply chain that supplies consumables and equipment inputs to wafer fabs.
The company is organized into two reporting segments. The Materials Solutions (MS) segment supplies materials-based inputs such as chemical vapor deposition (CVD) and atomic layer deposition (ALD) precursors, chemical mechanical planarization (CMP) slurries and pads, ion implantation specialty gases, and formulated etch and clean chemistries. The Advanced Purity Solutions (APS) segment provides filtration, purification, and contamination-control products used throughout semiconductor manufacturing processes.
Entegris customer base spans the semiconductor value chain, including logic and memory device manufacturers, semiconductor equipment makers, gas and chemical suppliers, wafer growers, and outsourced semiconductor assembly and test (OSAT) facilities. Beyond semiconductors, the company also serves flat panel display equipment makers, hard disk drive component manufacturers, and customers in solar, life sciences, electrical discharge machining, glass, aerospace, and biomedical device manufacturing.
- AI chip demand lifts specialty deposition materials orders
- Taiwan and Korea fab expansions fuel Materials Solutions growth
- China export controls threaten Advanced Purity Solutions revenue
| Net Income: 392.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 3.28 > 1.0 |
| NWC/Revenue: 34.01% < 20% (prev 37.37%; Δ -3.36% < -1%) |
| CFO/TA 0.09 > 3% & CFO 798.0m > Net Income 392.8m |
| Net Debt (3.10b) to EBITDA (954.5m): 3.25 < 3 |
| Current Ratio: 2.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (153.9m) vs 12m ago 1.05% < -2% |
| Gross Margin: 47.14% > 18% (prev 43.46%; Δ 3.68% > 0.5%) |
| Asset Turnover: 41.61% > 50% (prev 38.36%; Δ 3.25% > 0%) |
| Interest Coverage Ratio: 3.41 > 6 (EBIT TTM 648.5m / Interest Expense TTM 189.9m) |
| A: 0.14 (Total Current Assets 1.92b - Total Current Liabilities 722.1m) / Total Assets 8.54b |
| B: 0.22 (Retained Earnings 1.86b / Total Assets 8.54b) |
| C: 0.08 (EBIT TTM 648.5m / Avg Total Assets 8.47b) |
| D: 1.03 (Book Value of Equity 4.33b / Total Liabilities 4.21b) |
| Altman-Z'' = 3.22 = A |
| DSRI: 1.06 (Receivables 625.2m/539.0m, Revenue 3.52b/3.22b) |
| GMI: 0.92 (GM 43.46% / 47.14%) |
| AQI: 0.97 (AQ_t 0.57 / AQ_t-1 0.59) |
| SGI: 1.09 (Revenue 3.52b / 3.22b) |
| TATA: -0.05 (NI 392.8m - CFO 798.0m) / TA 8.54b) |
| Beneish M = -3.00 (Cap -4..+1) = AA |
As of November 20, 2026, the stock is trading at USD 138.14 with a total of 2,390,455 shares traded. Over the past week, the price has changed by -9.84%, over one month by -4.35%, over three months by -4.19% and over the past year by +87.83%.
Current recommended Stop Loss: 123.10 (which is 10.9% or 1.4 ATR below the current price).
Entegris has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ENTG.
- StrongBuy: 10
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 190.5 | 37.9% |
P/E Trailing = 57.358
P/E Forward = 28.2486
P/S = 6.3904
P/B = 5.1984
P/EG = 1.133
Revenue TTM = 3.52b USD
EBIT TTM = 648.5m USD
EBITDA TTM = 954.5m USD
Long Term Debt = 3.26b USD (from longTermDebt, last quarter)
Short Term Debt = 15.8m USD (from shortTermDebt, last fiscal year)
Debt = 3.46b USD (from shortLongTermDebtTotal, last quarter) + Leases 100.4m
Net Debt = 3.10b USD (calculated: Debt 3.46b - CCE 356.5m)
Enterprise Value = 25.6b USD (22.5b + Debt 3.46b - CCE 356.5m)
Interest Coverage Ratio = 3.41 (Ebit TTM 648.5m / Interest Expense TTM 189.9m)
EV/FCF = 41.61x (Enterprise Value 25.6b / FCF TTM 616.0m)
FCF Yield = 2.40% (FCF TTM 616.0m / Enterprise Value 25.6b)
FCF Margin = 17.48% (FCF TTM 616.0m / Revenue TTM 3.52b)
Net Margin = 11.14% (Net Income TTM 392.8m / Revenue TTM 3.52b)
Gross Margin = 47.14% ((Revenue TTM 3.52b - Cost of Revenue TTM 1.86b) / Revenue TTM)
Gross Margin QoQ = 49.74% (prev 47.55%)
Tobins Q-Ratio = 3.00 (Enterprise Value 25.6b / Total Assets 8.54b)
Interest Expense / Debt = 5.49% (Interest Expense 189.9m / Debt 3.46b)
Taxrate = 11.63% (51.7m / 444.5m)
NOPAT = 573.1m (EBIT 648.5m * (1 - 11.63%))
Current Ratio = 2.66 (Total Current Assets 1.92b / Total Current Liabilities 722.1m)
Debt / Equity = 0.80 (Debt 3.46b / totalStockholderEquity, last quarter 4.33b)
Debt / EBITDA = 3.25 (Net Debt 3.10b / EBITDA 954.5m)
Debt / FCF = 5.04 (Net Debt 3.10b / FCF TTM 616.0m)
Total Stockholder Equity = 4.12b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.64% (Net Income 392.8m / Total Assets 8.54b)
RoE = 9.53% (Net Income TTM 392.8m / Total Stockholder Equity 4.12b)
RoCE = 8.78% (EBIT 648.5m / Capital Employed (Equity 4.12b + L.T.Debt 3.26b))
RoIC = 7.48% (NOPAT 573.1m / Invested Capital 7.66b)
WACC = 13.96% (E(22.5b)/V(26.0b) * Re(15.36%) + D(3.46b)/V(26.0b) * Rd(5.49%) * (1-Tc(0.12)))
Discount Rate = 15.36% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 92.22 | Cagr: 0.61%
[DCF] Terminal Value 62.01% ; FCFF base≈501.9m ; Y1≈575.4m ; Y5≈846.8m
[DCF] Fair Price = 21.27 (EV 6.36b - Net Debt 3.10b = Equity 3.25b / Shares 152.8m; r=13.96% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 76.92 | EPS CAGR: 8.36% | SUE: 3.99 | # QB: 4
Revenue Correlation: -9.53 | Revenue CAGR: -0.37% | SUE: 3.34 | # QB: 2
EPS current Quarter (2027-03-31): EPS=1.22 | Chg30d=+9.47% | Revisions=+67% | Analysts=10
EPS current Year (2026-12-31): EPS=4.37 | Chg30d=+11.34% | Revisions=+77% | GrowthEPS=+58.8% | GrowthRev=+17.0%
EPS next Year (2027-12-31): EPS=5.68 | Chg30d=+12.35% | Revisions=+79% | GrowthEPS=+30.0% | GrowthRev=+15.1%
[Analyst] Revisions Ratio: +90% (up=27, down=0)